Chest Medicine (all articles)
What’s the difference between viral shedding and reinfection with COVID-19?
2 Dec, 2020 | 07:29h | UTCWhat’s the difference between viral shedding and reinfection with COVID-19? – The Conversation
Systematic review: Outdoor transmission of SARS-CoV-2 and other respiratory viruses. “The odds of indoor transmission was very high compared to outdoors (18.7 times)”
2 Dec, 2020 | 07:19h | UTC
Commentary on Twitter
Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review https://t.co/lmWQNgpIfd Existing evidence supports the wide-held belief that the the risk of #SARSCoV2 transmission is lower outdoors (< 10%).
— Carlos del Rio (@CarlosdelRio7) December 1, 2020
NICE COVID-19 guideline: Prevention of thromboembolism in patients with COVID-19. “For patients who are having advanced respiratory support: consider increasing pharmacological VTE prophylaxis to an intermediate dose”
1 Dec, 2020 | 08:19h | UTC
Moderna released more Covid-19 vaccine results. They’re very encouraging.
1 Dec, 2020 | 08:15h | UTCModerna released more Covid-19 vaccine results. They’re very encouraging. – Vox
Commentaries: ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 – Science AND Moderna to submit Covid-19 vaccine to FDA as full results show 94% efficacy – STAT AND More Good News For Moderna’s COVID-19 Vaccine Candidate – NPR AND Moderna to seek emergency authorization for COVID-19 vaccine – CIDRAP
Commentary on Twitter
Moderna has announced the final results of the 30,000-person efficacy trial for its #COVID19 vaccine candidate, reporting that the vaccine had 100% efficacy against severe disease. https://t.co/Cgg0I5nv9r
— News from Science (@NewsfromScience) November 30, 2020
Opinion: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data
1 Dec, 2020 | 08:13h | UTC
Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
1 Dec, 2020 | 08:08h | UTCCommentary: Gout drug Colchicine to be tested as COVID-19 treatment in UK trial – Reuters
Critically ill patients with COVID-19: A narrative review on prone position
1 Dec, 2020 | 08:07h | UTCCritically Ill Patients with COVID-19: A Narrative Review on Prone Position – Pulmonary Therapy
Report: SARS-CoV-2 setting-specific transmission rates. Households showed the highest transmission rates (21.1%). Asymptomatic infections do occur but much less efficiently than symptomatic infection.
30 Nov, 2020 | 01:01h | UTCFull report: SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis – Imperial College London
No evidence for increased transmissibility from mutations in SARS-CoV-2
30 Nov, 2020 | 01:06h | UTCCommentaries: Mutations not making coronavirus able to spread more rapidly -study – Reuters AND Covid-19 has NOT become more infectious: Study identifies almost 13,000 coronavirus mutations but none – including the dominant D614G strain – made it better at spreading – Daily Mail
Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany estimated at 0.36%
30 Nov, 2020 | 01:02h | UTCInfection fatality rate of SARS-CoV2 in a super-spreading event in Germany – Nature Communications
Long Covid: Comprehensive health assessment three months after recovery from acute COVID-19 revealed problems in several health domains in a substantial number of patients
27 Nov, 2020 | 08:33h | UTC
An artificial intelligence algorithm can detect COVID-19 on chest radiographs with accuracy and speed
27 Nov, 2020 | 08:31h | UTCCommentaries: AI system bests radiologists in spotting COVID-19 in lungs – CIDRAP AND AI detects COVID-19 on chest x-rays with accuracy and speed – Northwestern University
CDC Study showing decline in SARS-CoV-2 antibodies after infection suggests antibody surveys underestimate infections
26 Nov, 2020 | 09:08h | UTCCommentary: COVID-19 antibody surveys underestimate infections: study – MedicalXpress
Commentary on Twitter (Thread – Click for more)
1/?Precipitous decline in #SARSCoV2 antibodies: study participants who'd been infected and had detectable antibodies were retested 60 days later. 94% showed antibody decline & 28% had no detectable antibodies. They had "seroreverted". How that impacts reinfection risk is unknown pic.twitter.com/QsvQTE9jVH
— Dr. Ali Nouri (@AliNouriPhD) November 25, 2020
Randomized trial: Nebulized magnesium does not benefit children with acute refractory asthma treated in the emergency department
26 Nov, 2020 | 08:58h | UTCEffect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Nebulized Magnesium Of Little Value for Emergency Tx of Kids’ Asthma Attacks – Physician’s Weekly
Commentary on Twitter
This RCT found that nebulized magnesium does not decrease hospitalization for children with refractory acute asthma in the emergency department, compared to albuterol or placebo https://t.co/9NjgPztY6V @sickkids #VisualAbstract
— JAMA (@JAMA_current) November 24, 2020
Randomized trial: Convalescent Plasma does not improve clinical status or overall mortality in severe Covid-19 pneumonia
25 Nov, 2020 | 09:17h | UTCCommentary: New trial of convalescent plasma for covid-19 falls flat, another setback for hyped treatment – Brief19
Commentary on Twitter
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia @NEJM A well conducted RCT shows no significant differences in clinical status or overall mortality between patients treated with CP and those who received placebo. https://t.co/C6NylbO2At
— Carlos del Rio (@CarlosdelRio7) November 24, 2020
Cluster-randomized trial: Postexposure hydroxychloroquine does not prevent Covid-19 in healthy persons exposed to a PCR-positive case patient
25 Nov, 2020 | 09:15h | UTC
Commentary on Twitter
Another RCT in @NEJM of outpatient treatment with Hydroxychloroquine in high risk folks to prevent COVID transmission
No benefit
But about 10X rate of adverse events in HCQ group
Happy to keep studying HCQ
But it really doesn't look like it workshttps://t.co/9nAfir0CMX
— Ashish K. Jha, MD, MPH (@ashishkjha) November 24, 2020
With more data on its COVID-19 vaccine, Russian institute offers new evidence of success
25 Nov, 2020 | 09:13h | UTCWith more data on its COVID-19 vaccine, Russian institute offers new evidence of success – Science
Commentaries: Expert reaction to press release reporting the second interim analysis of the efficacy of the Sputnik V vaccine – Science Media Centre AND Russia says Sputnik V virus vaccine 95% effective – MedicalXpress
Latest COVID-19 guidelines come out against bamlanivimab, remdesivir
25 Nov, 2020 | 09:10h | UTCLatest COVID-19 guidelines come out against bamlanivimab, remdesivir – ACP Internist
Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19
24 Nov, 2020 | 09:34h | UTCDiagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19 – JAMA
Commentary on Twitter
Arterial and venous thrombosis are common in #COVID19, especially in critically ill patients. Thromboprophylaxis should be considered for all hospitalized patients with COVID-19 in the absence of contraindications https://t.co/sjqL7MqGLX
— JAMA (@JAMA_current) November 23, 2020
Why does the AstraZeneca-Oxford COVID-19 vaccine’s efficacy vary so much? Here’s what we know
24 Nov, 2020 | 09:30h | UTCWhy Does the AstraZeneca COVID-19 Vaccine’s Efficacy Vary So Much? Here’s What We Know – TIME
Related: Why Oxford’s positive COVID vaccine results are puzzling scientists – Nature
Why the AstraZeneca-Oxford Covid-19 vaccine is different. It does not require extremely cold temperatures for storage, and the price will be “a fraction” of the expense of the other vaccine candidates
24 Nov, 2020 | 09:32h | UTCWhy the AstraZeneca-Oxford Covid-19 vaccine is different – Vox
Emergency COVID-vaccine approvals pose a dilemma for scientists. It could complicate efforts to study long-term outcomes, such as safety, how long protection lasts and whether the jab prevents infection or just the disease
24 Nov, 2020 | 09:28h | UTCWhy emergency COVID-vaccine approvals pose a dilemma for scientists – Nature
Data show hospitalized Covid-19 patients are surviving at higher rates, but surge in cases could roll back gains
24 Nov, 2020 | 09:25h | UTC
Covid-19: Oxford University vaccine shows 70% protection
23 Nov, 2020 | 09:54h | UTCCovid-19: Oxford University vaccine shows 70% protection – BBC
News release: Oxford University breakthrough on global COVID-19 vaccine
Commentary on Twitter
Today marks an important milestone in the fight against #COVID19. Interim data show the #OxfordVaccine is 70.4% effective, & tests on two dose regimens show that it could be 90%, moving us one step closer to supplying it at low cost around the world>> https://t.co/fnHnKSqftT pic.twitter.com/2KYXPxFNz1
— University of Oxford (@UniofOxford) November 23, 2020
Meta-analysis: SARSCoV2 most contagious within the first 5 days of symptom onset
23 Nov, 2020 | 09:53h | UTCCommentaries: COVID-19 most contagious in first 5 days of illness, study finds – CIDRAP AND Infectiousness peaks early in COVID-19 patients, emphasising the need to rapidly isolate cases – The Lancet AND Covid-19 carriers ‘most infectious earlier on’ – BBC
Commentary on Twitter (thread – click for more)
Our systematic review and meta-analysis on #SARSCoV2, #SARSCoV & #MERSCoV viral load dynamics, duration of viral shedding & infectiousness out now in @LancetMicrobe ?@mugecevik @silverfoxdoc @CVRinfo @UofGlasgow @Infection_StAnd https://t.co/Tac3A2RR3E
— Antonia Ho (@DrToniHo) November 20, 2020